Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SMND-309 is a metabolite of salvianolic acid B. It also shows neuroprotective effects in cultured neurons and in permanent middle cerebral artery occlusion rats.
Description | SMND-309 is a metabolite of salvianolic acid B. It also shows neuroprotective effects in cultured neurons and in permanent middle cerebral artery occlusion rats. |
In vivo | SMND-309 treatment decreases the liver damage and the liver fibrosis grade. SMND-309 also reduces the elevation in the malondialdehyde level and restored the decrease in superoxide dismutase and glutathione peroxidase activities. SMND-309 treatment powerfully down-regulated the expression of connective tissue growth factor (CTGF) in serum and liver. SMND-309 (2.5-10 mg/kg; oral intragastric; once a day; for 4 weeks; male Sprague-Dawley rats) treatment ameliorates liver function and decreases the elevation of serum hyaluronic acid, laminin, procollagen type III levels and hydroxyproline content in liver tissue [1]. |
Molecular Weight | 358.302 |
Formula | C18H14O8 |
CAS No. | 1065559-56-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 3.7 mg/mL (10.33 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SMND-309 1065559-56-9 Others SMND 309 SMND309 inhibitor inhibit